We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat
Read MoreHide Full Article
Reata Pharmaceuticals Inc. reported third-quarter 2021 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.32.
However, the above loss included stock-based compensation and a non-cash interest expense. Adjusted loss for the quarter was $1.27 per share, narrower than $1.31 per share recorded in the year-ago period.
Total revenues, comprising collaboration revenues, were $7.4 million compared with $1.4 million in the year-ago quarter. The top line also beat the Zacks Consensus Estimate of $1.4 million.
Shares of Reata were up 1.7% on Monday, following better-than-expected results. However, the company’s shares have declined 13.5% so far this year compared with the industry’s decrease of 12.5%.
Image Source: Zacks Investment Research
Operating Expenses & Cash Position
Adjusted research and development expenses rose 3.3% year over year to $34 million.
General and administrative expenses were $25.7 million, up 40.4% from the year-ago period due to increased commercial launch readiness activities and higher personnel costs.
The company had cash and cash equivalents of $713.2 million as of Sep 30, 2021, compared with $755.7 million as of Jun 30, 2021. The company expects its cash resources to fund operations through mid-2024.
Pipeline Update
Reata has developed its lead pipeline candidates — bardoxolone methyl (bardoxolone) and omaveloxolone — for rare forms of chronic kidney disease (“CKD”) and neurological diseases, respectively. Please note that Reata re-acquired the development, manufacturing and commercialization rights related to omaveloxolone and bardoxolone from AbbVie (ABBV - Free Report) last year.
In April, Reata’s new drug application (“NDA”) seeking approval for bardoxolone as a potential treatment for CKD caused by Alport syndrome was accepted by the FDA. An Advisory Committee meeting is scheduled on Dec 8 for discussing the NDA. A final decision from the FDA is expected by Feb 25, 2022. The company has also submitted a regulatory application in Europe seeking approval for bardoxolone for the same indication last month.
In September, Reata successfully completed a pre-NDA meeting with the FDA, discussing a planned NDA submission for another pipeline candidate, omaveloxolone. Following the meeting, the company is planning to submit an NDA for the same in the first quarter of 2022.
Reata is also developing bardoxolone for treating autosomal dominant polycystic kidney disease (“ADPKD”) in the phase III FALCON study. The company is currently preparing protocol amendments to the FALCON study. The primary endpoint now will be Year 2 off-treatment analysis. The company has decided not to unblind the study until after its completion. The study’s patient enrollment sample size will also be increased from 550 to 700 patients. The company expects to reach the increased enrollment target by mid-2022.
The candidate is also being evaluated in a phase II study (MERLIN) in patients with CKD at risk of rapid progression to end-stage kidney disease. Data from the study is expected in the first quarter of 2022.
Reata Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Estimates for Fulcrum have narrowed from a loss per share of $2.68 to $2.62 for 2021 and from $2.77 to $2.70 for 2022 in the past 30 days. The company beat estimates in the last four quarters, with the average earnings surprise being 12.29%. The stock is up 73.3% so far this year.
Estimates for Gritstone have improved from a loss per share of $1.02 to 98 cents for 2021 and from $1.22 to $1.15 for 2022 in the past 30 days. The company delivered an earnings surprise in each of the last four quarters, with the average beat being 44.42%. The stock has risen 183% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat
Reata Pharmaceuticals Inc. reported third-quarter 2021 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.32.
However, the above loss included stock-based compensation and a non-cash interest expense. Adjusted loss for the quarter was $1.27 per share, narrower than $1.31 per share recorded in the year-ago period.
Total revenues, comprising collaboration revenues, were $7.4 million compared with $1.4 million in the year-ago quarter. The top line also beat the Zacks Consensus Estimate of $1.4 million.
Shares of Reata were up 1.7% on Monday, following better-than-expected results. However, the company’s shares have declined 13.5% so far this year compared with the industry’s decrease of 12.5%.
Operating Expenses & Cash Position
Adjusted research and development expenses rose 3.3% year over year to $34 million.
General and administrative expenses were $25.7 million, up 40.4% from the year-ago period due to increased commercial launch readiness activities and higher personnel costs.
The company had cash and cash equivalents of $713.2 million as of Sep 30, 2021, compared with $755.7 million as of Jun 30, 2021. The company expects its cash resources to fund operations through mid-2024.
Pipeline Update
Reata has developed its lead pipeline candidates — bardoxolone methyl (bardoxolone) and omaveloxolone — for rare forms of chronic kidney disease (“CKD”) and neurological diseases, respectively. Please note that Reata re-acquired the development, manufacturing and commercialization rights related to omaveloxolone and bardoxolone from AbbVie (ABBV - Free Report) last year.
In April, Reata’s new drug application (“NDA”) seeking approval for bardoxolone as a potential treatment for CKD caused by Alport syndrome was accepted by the FDA. An Advisory Committee meeting is scheduled on Dec 8 for discussing the NDA. A final decision from the FDA is expected by Feb 25, 2022. The company has also submitted a regulatory application in Europe seeking approval for bardoxolone for the same indication last month.
In September, Reata successfully completed a pre-NDA meeting with the FDA, discussing a planned NDA submission for another pipeline candidate, omaveloxolone. Following the meeting, the company is planning to submit an NDA for the same in the first quarter of 2022.
Reata is also developing bardoxolone for treating autosomal dominant polycystic kidney disease (“ADPKD”) in the phase III FALCON study. The company is currently preparing protocol amendments to the FALCON study. The primary endpoint now will be Year 2 off-treatment analysis. The company has decided not to unblind the study until after its completion. The study’s patient enrollment sample size will also be increased from 550 to 700 patients. The company expects to reach the increased enrollment target by mid-2022.
The candidate is also being evaluated in a phase II study (MERLIN) in patients with CKD at risk of rapid progression to end-stage kidney disease. Data from the study is expected in the first quarter of 2022.
Reata Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Reata Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Reata Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Reata currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the same sector include Fulcrum Therapeutics (FULC - Free Report) and Gritstone bio (GRTS - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Fulcrum have narrowed from a loss per share of $2.68 to $2.62 for 2021 and from $2.77 to $2.70 for 2022 in the past 30 days. The company beat estimates in the last four quarters, with the average earnings surprise being 12.29%. The stock is up 73.3% so far this year.
Estimates for Gritstone have improved from a loss per share of $1.02 to 98 cents for 2021 and from $1.22 to $1.15 for 2022 in the past 30 days. The company delivered an earnings surprise in each of the last four quarters, with the average beat being 44.42%. The stock has risen 183% so far this year.